Attitudes Toward Striving for Quality and Length of Life Among Patients With Advanced Cancer and a Poor Prognosis

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Hanneke W.M. Van Laarhoven

Consulting or Advisory Role: Bristol Myers Squibb, Servier, Dragonfly Therapeutics, Merck

Research Funding: Bristol Myers Squibb (Inst), Bayer Schering Pharma (Inst), Celgene (Inst), Janssen-Cilag (Inst), Lilly (Inst), Nordic Group (Inst), Philips Healthcare (Inst), Roche (Inst), Merck Sharp & Dohme (Inst), Servier (Inst), Merck KGaA (Inst), Incyte (Inst)

Travel, Accommodations, Expenses: AstraZeneca

Petronella B. Ottevanger

Consulting or Advisory Role: AstraZeneca (Inst), GlaxoSmithKline (Inst), Nykode (Inst)

Serge E. Dohmen

Other Relationship: Roche

Filip Y.F.L. de Vos

Research Funding: Novartis (Inst), Bristol Myers Squibb (Inst), Agios (Inst)

No other potential conflicts of interest were reported.